Loading…
← CockpitCompetitor Analysis › DIVISLAB.NS Divi's LaboratoriesOpen in the cockpit ↗

Divi's LaboratoriesDIVISLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Leading Indian contract manufacturer of active pharmaceutical ingredients (APIs) for global generic and innovator drugmakers.

≈ India's Lonza / Catalent for API/CDMO manufacturingMomentum leader 96
Mkt cap
$31.3B
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$96.6M
20-day average traded
Fwd P/E
73.5×
forward earnings
ROIC−WACC
+6.7 pp
WACC 12.9%
Hurdle
+38 pp
Req g minus delivered
Next earnings
85 days
11 Feb 2027
Close · INR₹11,049
1D-0.9%
1W-2.8%
1M+21.6%
3M+28.7%
6M+59.9%
YTD+72.8%
1Y+69.5%
ATR %2.9%
Beta0.59
52w lowhigh6.5% off high

What Divi's Laboratories does

Leading Indian contract manufacturer of active pharmaceutical ingredients (APIs) for global generic and innovator drugmakers.

Sells active ingredients, the chemical that makes a drug work, to generic makers, and manufactures custom molecules for innovator drugmakers under long-term confidential supply arrangements. Most of its sales are exports. The founder, Murali Divi, and his family remain the controlling shareholders.

In one line: India's Lonza / Catalent for API/CDMO manufacturing.

Products and services

  • Generic APIs
  • Custom synthesis / CDMO for innovator pharma
  • Nutraceutical ingredients

Customers

  • Global generic-drug manufacturers
  • Multinational innovator pharma companies (custom s
  • Nutraceutical companies

Where it sits in the supply chain

  • Pharmaceutical ingredients (CDMO)
  • API & custom-synthesis manufacturing
  • Generic APIs, custom synthesis (CDMO)…

What could go right

  • China+1 API sourcing diversification by global pharma
  • Growing CDMO outsourcing demand

What could go wrong

  • Customer/molecule concentration risk
  • Regulatory (FDA) plant-inspection risk

Moat: narrow (process know-how, regulatory licence, scale). US FDA/EU-approved manufacturing scale and complex-chemistry expertise create high qualification barriers.

Headquarters: Hyderabad, India · Founded: 1990 · Employees: 19,292

Named competitors

Divi's Laboratories at a glance

Size Divi's Laboratories (DIVISLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $31.3B, the 30th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹11,049 on 18 Nov 2026.

Performance Over six months the shares gained 59.9%, against +8.2% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 21.6% over the last twelve months (peer median +16.4%); the operating margin is 33.9% (peer median 17.8%).

Valuation It trades at 73.5× forward earnings against a peer median of 19.8× (most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 6.7 points above its cost of capital (12.9% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026DIVISLAB.NS 160Peer median 108
Six months, rebased to 100: Divi's Laboratories against the median of its 20 peers (local-currency closes).

Divi's Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹122B₹105B₹93.6B₹78.3B₹77.5B
Revenue growth—+13%+19%+1%—
Gross profit₹58.5B₹36.5B₹31.9B₹24.1B₹25.5B
EBITDA₹46.5B₹34.8B₹30.4B₹23.3B₹24.1B
Net income₹33.6B₹25.7B₹21.9B₹16.0B₹18.2B
Free cash flown/a₹4.97B₹5.08B₹5.56B₹21.9B
Capital expendituren/a₹25.2B₹14.4B₹10.0B₹4.73B
Total debt₹60.0M₹70.0M₹40.0M₹30.0M₹32.6M

Quarterly statements and history in the cockpit →

Divi's Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%45684503ZTSROIVBIIBINSM3692RPRXHLN4578INCYSDZVTRSSIG1276688235SUNPHARMAALNYGALD1801DIVISLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Divi's Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×45684503ZTS3692INCYSDZVTRSSIG688235SUNPHARMAALNYGALD1801DIVISLAB.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Divi's Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%+80%0%25%50%75%45684503ZTSBIIB3692HLNINCYSIG688235SUNPHARMAALNYGALD1801DIVISLAB.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Divi's Laboratories is the large dot.

Divi's Laboratories competitors and peer comparison

Head to head with its named competitors (DIVISLAB.NS vs LONN.SW vs LAURUSLABS.NS vs SYNGENE.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Laurus Labs LAURUSLABS.NS$13.4B+73%+23%24%76.4×51.2%
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%

How Divi's Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Divi's Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureDIVISLAB.NSPeer medianRank in peer set
1-month return+21.6%+3.9%2nd highest of 21
6-month return+59.9%+8.2%highest of 21
Distance from 52-week high-6.5%-10.3%8th highest of 21
Revenue growth (TTM)+21.6%+16.4%9th highest of 21
Operating margin33.9%17.8%4th highest of 21
Forward P/E73.5×19.8×most expensive of 19
Growth the price implies (Req g, 7 yrs)47.1%9.6%most demanding of 19
Growth delivered (Del g)+8.9%+11.1%9th lowest of 19
Hurdle (Req g minus delivered)+38.2 pp+1.5 ppmost demanding of 19
ROIC minus cost of capital+6.7 pp+4.8 pp9th highest of 21
EV / EBITDA62.5×21.0×most expensive of 18
Net debt / EBITDA-0.5×0.2×7th least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%n/an/an/a
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
Insmed INSMUnited States$26.3B+3%+240%-42%n/an/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%25.8×7.9%+10.8%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Incyte INCYUnited States$24.0B+21%+25%12%15.1×14.2%+14.0%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Viatris VTRSUnited States$23.3B+23%+5%11%7.5×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%38.4×28.9%+26.1%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%28.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%

Questions

Who are Divi's Laboratories's main competitors?
Named competitors: Lonza Group (LONN.SW), Laurus Labs (LAURUSLABS.NS), Syngene International (SYNGENE.NS), Cambrex Corporation (private or unlisted). The cockpit's measured peer set (industry) also includes Daiichi Sankyo (4568.T), Astellas Pharma (4503.T), Zoetis (ZTS), Roivant Sciences (ROIV), Biogen (BIIB), Insmed (INSM).
Is Divi's Laboratories expensive compared with its peers?
On forward p/e it trades at 73.5× against a peer median of 19.8×, most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Divi's Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +59.9% against +8.2% for the median peer; over one year +69.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.